Wegovy's Semaglutide Transforms Obesity Treatment with Lasting Results
Semaglutide, sold under the brand Wegovy®, is helping people with obesity lose significant weight. The medication, part of a group called GLP-1s, can lead to reductions of 15% to 25% of body weight within a year. Early changes, such as feeling fuller and fewer cravings, often appear within the first month of treatment. Patients using semaglutide typically notice improvements in blood sugar and weight loss in the first four weeks. However, progress may not follow a straight path, and healthcare providers play a key role in tracking results and adjusting doses as needed. They also offer advice on diet, exercise, and long-term habits.
Stopping the medication can bring challenges. Over half of those who quit may keep the weight off or even lose more after a year. But for others, hunger returns, metabolism slows, and 'food noise'—constant thoughts about eating—comes back. Without continued treatment, full weight regain is possible within two years. Long-term use has added benefits. Studies show that taking semaglutide for four years lowers the risk of heart attacks, strokes, and other cardiovascular problems. A personalised maintenance dose can also help sustain weight loss over time.
Semaglutide offers a way to manage obesity with measurable results, but its effects depend on continued use. Healthcare support remains vital for adjusting treatment and maintaining healthy habits. For those who stay on the medication, the benefits extend beyond weight loss to include better heart health.
